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The paper provides a systematic review on the cost-of-illness studies in an age-associated condition 
with high prevalence, benign prostatic hyperplasia (BPH), published in Medline between 2005 and 2015. 
Overall 11 studies were included, which were conducted in 8 countries. In the US, the annual direct 
medical costs per patient ranged from $255 to $5,729, while in Europe from €253 to €1,251. In 2008, in 
the UK total annual direct medical costs of BPH were £180.8 million at national level. In the US, overall 
costs of BPH management in the private sector were estimated at $3.9 billion annually, of which $500 
million was attributable to productivity loss (year 1999). Due to demographic factors and possible 
surgical innovations in the field of urology, the costs of BPH are likely to increase in the future. Over the 
next decade the age of retirement is projected to rise, consequently, the indirect costs related to aging-
associated conditions such as BPH are expected to soar. To promote the transparent and cost -effective 
management of BPH, development of rational clinical guidelines would be essential that may lead to 
significant improvement in quality of care as well as reduction in healthcare expenditure. 
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1. Introduction 
 
Benign prostatic hyperplasia (BPH) manifesting in lower urinary tract symptoms (LUTS) is 
one of the most common urological conditions with a prevalence of 10-46% in patients over 
40 (Speakman et al. 2014). Ageing – the main risk factor for developing BPH – is a major 
public policy concern, particularly in the fields of social security, pension-systems, and 
financing and provision of healthcare services (Shrestha 2000). By 2050, there will be 58 
million people over 65 living in the European Union (European Commission 2008). 
Healthcare expenditure in the EU-27 is projected to increase from 7.1% to 8.4% of GDP from 
2010 to 2060 purely attributable to the effect of an ageing population on healthcare spending 
(European Commission 2012).  
Ageing-associated diseases, such as BPH, type 2 diabetes, dementia, osteoporosis, arthritis, 
pemphigus, bladder cancer and prostate cancer, have become major cost drivers of healthcare 
financing (Brodszky et al. 2009, Ersek et al. 2010, Hever et al. 2014, Pentek et al. 2008, 
Rencz et al. 2014a, Rencz et al. 2014b, Rencz et al. 2015b, Tamas et al. 2014). Given the 
increasing longevity, the demographic ageing observed in the developed countries and the 
high prevalence of BPH, more and more men use health care services due to the symptoms of 
BPH (Boncz et al. 2014, Rencz 2012). Financing the rising demand for healthcare is a great 
challenge for societies and economies, particularly in times of recession when countries 
struggle to comply with austerity measures. The treatment of BPH typically depends on the 
severity of the disease and may involve watchful waiting, pharmacotherapy and a number of 
surgical procedures. However, costs of these can vary dramatically (Taub et al. 2006); 
therefore, the economic evaluations of these treatment modalities are very useful to promote 
cost-effectiveness in healthcare decision-making and facilitate the elimination of the existing 
inefficiencies from the system. In countries with well-established health technology 
assessment agencies, economic evaluations are key elements of healthcare decision-making 
(Gulacsi et al. 2014a, Gulacsi et al. 2014b, Gulacsi et al. 2014c). As the number of patients 
and as a consequence, costs are continuously increasing, a review of the literature is an 
appropriate starting point to explore and understand the economic burden imposed by BPH. 
Therefore, the objective of the current study is to provide a literature review of cost-of-illness 
studies in BPH conducted in the past 10 years, and to explore inter-country differences and 
main cost drivers.  
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2. Methods 
 
A systematic literature search was performed in the most extensive medical literature 
database, namely Medline via PubMed. The search strategy consisted of free-text terms and 
medical subject headings related to the disease or the cost analysis.1 The key words for the 
search were the following: healthcare costs, cost-of-illness, benign prostatic hyperplasia. The 
search was limited to studies published in English between 1st January, 2005 and 25th March, 
2015. Inclusion criteria to the study were: (i) original paper (excluding review or letter), (ii) 
reports of cost-of-illness studies in BPH (excluding studies where BPH was examined as a co-
morbidity of another condition). Studies evaluating only a few selected types of treatment, 
e.g. limited to surgical treatments or selected medications only, were excluded. The papers 
were selected by two independent reviewer. Study design, year of publication, geographical 
location, perspective of cost analysis, patient numbers, cost categories assessed, year of 
costing and cost results were retrieved from all included studies.  
 
3. Results 
 
3.1 Characteristics of the papers 
Literature search yielded overall 159 hits, of which 148 were excluded for the following 
reasons: 84 studies were not involving BPH or did not report costs, 12 papers were not 
original articles, 16 studies were other types of economic evaluations (e.g. cost-effectiveness 
analysis, cost-minimisation analysis) and 36 studies evaluated only a few treatment types or 
did not report per patient costs, but only costs of the total cohort or the total patient population 
in a country. Eventually, 11 papers meeting the inclusion and exclusion criteria were included 
in the current review (Table 1). 
                                                 
1
Medline search strategy: ((bph[Title/Abstract]) OR prostatic hyperplasia[MeSH Terms] OR prostatic 
hyperplasia[Title/Abstract])) AND ((((costs or cost analysis[MeSH Terms] OR health expenditures[MeSH 
Terms]) OR health care costs[MeSH Terms]) OR cost of illness[MeSH Terms]) OR cost[Title/Abstract] OR 
economic burden[Title/Abstract]) NOT review[publication type] 
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Table 1. Per patient costs of BPH 
Author (year) Study design  
Study 
year 
Countries 
Patients 
(N) 
Perspective 
Costs categories 
assessed 
Year of 
costs 
Time horizon Results 
van Exel, 2006 
cross-sectional 
questionnaire survey 
 
Feb. 
2000 – 
May 
2003 
France 991 
payers’ 
perspective 
per patient direct 
medical costs incl. 
diagnostics, treatments 
and costs of 
complications 
€, 2003 1 year 
€639 
Germany 443 €513 
Italy 671 €633 
Poland 1,823 €1,183 
Spain 952 €595 
UK 177 €292 
Cozar, 2013 
cross-sectional 
telephone interviews 
(with 153 GPs and 
154 urologists) 
April, 
May 
2010 
Spain NR 
payers’ 
perspective 
per patient direct 
medical costs incl. 
diagnostics, treatments  
€, 2012 1 year €253 -1,251 
Johansen, 2007 Markov model 2006 Norway 1,000 
payers’ and  
societal 
perspectives 
total costs incl. direct 
and indirect costs 
(productivity loss and 
leisure time loss) 
€, 2006 
4 years 
Payers’ perspective 
Medication: €1,703-
2,054 
TURP: €5,655 
Societal perspective 
Medication: €1,938-
2,555 
TURP: €7,638 
15.5 years 
Payers’ perspective 
Medication: €3,924-
4,946 
TURP: €6,164 
Societal perspective 
Medication: €4,315-
5,861 
TURP: €8,307 
Bellinger, 2012 
insurance claim 
database analysis  
2000 - 
2007 
US 40,253 
payers’ 
perspective 
per patient direct 
medical costs incl. 
diagnostics, treatments  
$, 2007 
1 year (first 
year after 
diagnosis) 
2000: $255 
2007: $344 
Saigal, 2005 
insurance claim 
database analysis  
1999 US 2,013 
payers’ 
perspective 
per patient direct 
medical costs 
$,1999 1 year 
without medical 
claim $4,193 
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with medical claim: 
$5,729 
Saigal, 2007 
insurance claim 
database analysis  
1997-
2002 
US 1,952 
payers’ 
perspective 
per patient direct 
medical costs 
$, 2002 5 years 
Medication first 
cohort: $2,193 
Surgery first cohort 
$12,699 
Strope, 2011 
insurance claim 
database analysis  
1999-
2007 
US NR 
payers’ 
perspective 
per patient direct 
medical costs 
$, 2007 1 month 
$35 – 527 (median 
$92) 
Disantostefano, 
2006 
Markov model 
 
2004 US 1,000 
societal 
perspective 
per patient treatment 
costs 
$, 2004 20 years 
1
st
 year: 
WW $195; AB 
$628; 
5-ARI $900; 
Combined therapy 
$1,333; TUMT 
$4,073; TURP 
$7,201 
SSQ years: 
WW $108; AB: 
$541; 
5-ARI $870; 
Combined therapy 
$1,247; TUMT $54; 
TURP $54 
5-ARI = 5-alpha-reductase inhibitor, AB = alpha-blocker, GP = general practitioner, NR = not reported, SSQ = subsequent, TUMT = Transurethral microwave therapy, TURP 
= Transurethral prostatectomy, WW = watchful waiting 
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Four studies were conducted in European countries and seven in the US. There was a 
multinational research involving six European countries (France, Germany, Italy, Poland, 
Spain, and the UK). There were 2 cross-sectional studies, 2 Markov model simulations and 7 
retrospective analyses of insurance claim databases, respectively. The methodologies used in 
the cross-sectional surveys were telephone interview and questionnaire survey, respectively. 
Sample sizes varied from 1,000 to 40,253 but two studies did not report the number of 
patients enrolled. For the cost calculation, nine studies applied payer’s perspective, one 
societal perspective and one both, respectively. The time horizon of the studies ranged 
between 1 month and 20 years (average expected lifetime for a BPH patient at the time of 
diagnosis) while the most commonly used time horizon was 1 year. Year of costs in the 
studies varied from 1998 to 2012.  
 
3.2 Costs 
Per patient costs were reported in 8 studies (Table 1), whereas nationwide costs, or costs of a 
larger cohort in 5 studies (Table 2). As for cost categories, 10 studies considered only direct 
medical costs and one both direct and indirect costs, respectively. In the study by 
Disantostefano et al. solely the costs of therapy were estimated. Apart from the direct costs, 
Johansen et al. included the loss of productivity as well as of leisure time in the indirect costs. 
The direct medical costs of BPH varied widely across studies. In the US, the annual direct 
medical costs per patient ranged between $255-5,729, while in Europe between €253-1,251. 
In Norway, costs were estimated at €1,703-7,638 and €3,924-8,307 in four- and 15.5-year 
horizons, respectively, depending on the treatment modalities and the perspective of the cost 
calculation. In the US, the 5-year direct medical costs were ranging from $2,193 to $12,699. 
Both in the US and Europe, mean costs associated with surgically treated patients exceeded 
those receiving pharmacological treatment. In the US, costs of patients with medical claim 
($5,729) were found higher compared to those without it ($4,193). 
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Table 2 Costs of larger patient cohorts or total costs at the national level 
Author (year) Study design Study year Countries Patients Perspective 
Costs 
categories 
assessed 
Year of 
costs 
Time frame Results 
Litwin, 2005 
insurance 
claim database 
analysis 
1998-2000 US nationwide 
payers’ 
perspective 
direct medical 
costs 
$, 1998 1 year $ 776 million 
Saigal, 2005 
insurance 
claim database 
analysis 
1999 US 
all privately 
insured patients 
payers’ 
perspective 
direct and 
indirect costs 
$, 1999 1 year $ 3.9 billion 
Wei, 2005 
insurance 
claim database 
analysis 
1990-2000 US nationwide 
payers’ 
perspective 
direct medical 
costs excl. 
outpatient drug 
costs 
$, 2000 1 year $ 1.1 billion 
Kirby, 2010 
Hospital 
Episode 
Statistics 
(HES) 
2007-2008 UK nationwide 
payers’ 
perspective direct medical 
costs 
£, 2008 1 year 
£180.8 
million 
Bellinger, 2012 
insurance 
claim database 
analysis 
2000 - 2007 US 
Medicare 5% 
cohort 
payers’ 
perspective 
direct medical 
costs 
$, 2007 
1 year (first 
year after 
diagnosis) 
$32.3 million 
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The Triumph project (Trans European Research into the use of Management Policies for 
LUTS suggestive of BPH) was a one-year prospective, cross-sectional, observational survey 
including 5,077 patients with LUTS suggestive of BPH from France, Germany, Italy, Poland, 
Spain and the UK (van Exel et al. 2006). Only direct medical costs were evaluated and data 
on possible complications such as acute urinary retention, bleeding, renal dysfunction, urinary 
tract infections, and bladder stones were collected as well. Although patients enrolled in the 
six countries were quite similar, treatment strategies differed by country. For instance, the 
average number of annual visits to the urologist ranged from 1.0 (France, Italy, UK) to 2.7 
(Germany), transabdominal ultrasonographies from 11% (UK) to 83% (Poland), transrectal 
ultrasonographies from 1% (UK) to 26% (France), Prostate Specific Antigen tests from 41% 
(Germany) to 88% (Spain), and free-flow studies from 4% (Italy) to 26% (Spain), 
respectively. The proportion of watchful waiting (WW) (i.e. regular follow-up without 
applying any specific treatment) was the lowest in Italy and Poland (20%), whereas the 
highest in the UK (69%). Rate of patients on alpha-blockers and phytotherapy ranged from 
2% (the UK) to 9% (Germany and France), and from 1.4% (Poland) to 16.5% (France), 
respectively. The lowest surgery rate was found in the UK (1.7%) and the highest in Poland 
(6.4%). Total direct medical costs of BPH in France, Germany, Italy, Poland, Spain, and the 
UK were estimated at €639, €513, €633, €1,337, €595 and €292, respectively (year 2003). 
Medications were identified as the most important cost drivers, as they accounted for about 
three quarters of the total treatment costs (range: from 40% in France to 89% in Poland). 
Costs of surgical procedures accounted for 15% of total costs and the diagnostic tests for 
approximately 8%, respectively. Higher severity was associated with higher costs both for 
voiding (mild $673, moderate $906 and severe $960) and storage symptoms ($623, $865 and 
$1,043) (van Exel et al. 2006). 
Estimations of costs spent on BPH at national level are available from the US and the UK. In 
2008, in the UK, the total annual direct medical costs of BPH at national level were £180.8 
million (Kirby et al. 2010). In the US, based on insurance claim expenditures, nationwide 
costs of BPH were $776 million in 1998 (Litwin et al. 2005), and $1.1 billion in 2000 (Wei et 
al. 2005), respectively. However, another study from 1999 reported that overall costs 
(including direct and indirect costs) of BPH management in the private sector were estimated 
at $3.9 billion annually (Saigal – Joyce 2005).  
4. Discussion 
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In the present review, evidence from 11 cost-of-illness studies in BPH, published in the past 
10 years, were summarized. The 11 studies were conducted in 8 countries covering Europe 
and the US. The direct medical costs per patient were estimated at $255-5,729 yearly in the 
US, while €253-1,251 in Europe. Despite the lack of up-to-date national expenditure data in 
most countries, based on per patient findings, total costs of disease at national level are 
estimated to be enormous in each country.  
Direct medical costs, including costs of physicians’ visits, hospital admissions, diagnostic 
tests and treatments, were responsible for the majority of the total costs. However, only a 
small proportion of men with BPH were reported to seek medical help (Rosen et al. 2003), 
suggesting that the direct costs might have been underestimated. Symptomatic BPH patients 
may develop complications such as acute urinary retention (AUR), especially when left 
untreated. Risk for men in their 80s to experience AUR within the next 5 years is nearly 1 in 3 
(Emberton et al. 1999). Such complications may significantly increase the direct medical 
costs of BPH. In 2007/2008 in the UK, the annual total costs associated with the major 
complications of BPH in the secondary care reached as much as £101.2 million at national 
level (Kirby et al. 2010).  
Most of the studies currently reviewed have concerned the direct medical costs related to 
BPH; however, considerable indirect costs may incur as well. Saigal and Joyce, based on data 
of more than 120,000 privately insured working-age males, found that an average employee 
missed 7.3 hours of work yearly due to BPH (approximately 7.1 hours due to outpatient care 
and 0.2 hours due to hospital admissions) (Saigal - Joyce 2005). In this study only a minority 
of the patients was absent from work in the past year (10%). Average work loss exceeded 9 
days yearly in those reporting some absence temporally related to BPH treatment. Indirect 
costs of privately insured employees were estimated at $500 million (year 1999). Costs 
related to presenteeism (i.e. reduced productivity while at work due to BPH) have not been 
assessed by any of the studies. Nevertheless, BPH has a detrimental effect on the quality of 
life (Fourcade et al. 2012, Schulz et al. 2002) similar to that experienced in epilepsy, chronic 
migraine, or in case of severe symptoms associated with psoriasis (Heredi et al. 2014, Moradi 
et al. 2015, Pentek et al. 2013, Rencz et al. 2015a, Rencz et al. 2014c). Urinary symptoms 
may bother patients while working, resulting in decreased productivity (presenteeism).  
As the population is ageing, the retirement age is increasing in the industrialized countries. 
The average official retirement age in the OECD-34 was 64.65 years in 2012, but in certain 
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countries, such as Australia, the US, Norway, Israel and Iceland, it is higher than 65 years 
(OECD 2012). Furthermore, in many developed countries, the effective retirement age may 
exceed the official one by even more than five years, e.g. in France, Belgium and Luxemburg. 
Over the next decade the retirement age is projected to soar, therefore, the indirect costs 
related to ageing-associated conditions such as BPH are expected to rise as well. In light of 
the findings of the present review, presenteeism due to BPH seems to be understudied. Future 
investigations are highly encouraged to explore the share of indirect costs between 
absenteeism and presenteeism.  
The potential limitations of this study involve heterogeneity of the studies in terms of sample 
sizes, characteristics of the patient populations, study designs, countries, variety of treatments 
used, differences in unit costs and methods for cost calculation. These make the direct 
comparisons between these studies difficult. Year of costing in the studies ranged between 
1999 and 2012. Since 1999, as the technology has evolved and new medicinal products have 
become available for the treatment of BPH, cost patterns could have changed. Moreover, this 
review did not evaluate studies which reported costs for a single or a limited number of 
selected treatment options.  
5. Conclusion 
In summary, BPH is an age-associated disease affecting more and more males over the age of 
40. Given the demographic ageing, increasing longevity and the high prevalence of the 
disease, BPH poses a significant economic burden on healthcare budgets in the developed 
countries. Due to demographic factors and possible surgical innovations in the field of 
urology, the costs of BPH are likely to increase in the future. The higher number of patients 
will require more trained urologists to ensure sufficient capacity for the optimized 
management of BPH. Over the next decade the retirement age is projected to rise, therefore, 
the indirect costs related to ageing-associated conditions such as BPH are expected to soar. To 
promote the transparent and cost-effective management of BPH, development of reasonable 
clinical guidelines would be essential that may lead to significant improvement in quality of 
care as well as reduction in healthcare expenditure. 
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